drugset
drugset / Press release

FluoGuide receives permission to start phase IIb trial in aggressive brain cancer

2022-08-30 · FluoGuide A/S · original fluoguide.com ↗

FG001 · regulatory

Copenhagen, Denmark, 30 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the company now has received the permission to start the phase IIb clinical trial with FG001.

The release as fetched from its publisher. fluoguide.com ↗